Cadila Healthcare inches closer to net profit upgrades

The company is on course to sort out various issues raised by the FDA

That the US Food and Drug Administration (FDA) did not make fresh observations after inspecting Cadila Healthcare's Moraiya plant in Gujarat could be a turning point for the company. This plant was responsible for more than 60 per cent of the company's US exports and was impacted ever since issues cropped in 2014. Regulatory issues aggravated after the company received a warning letter which forced it to implement remediation measures. The measures seem to have served the purpose, as the company did not receive any negative comments after the US regulator inspected the plant over the last two weeks. The